On May 31st, at the 6th World Chinese Neurosurgery Congress held in Nanjing, the first clinical practice guideline for the diagnosis and treatment of brain tumors in China, i.e., Chinese Molecular Diagnostic and Treatment Guidelines for Gliomas (hereinafter referred to as “the Guidelines”), was released. Associate Prof. Xuejun Li, Department of Neurosurgery, Xiangya Hospital, Central South University, participated in the drafting, revision and development of the Guidelines. Xuejun Li, Department of Neurosurgery, Xiangya Hospital, Central South University The World Chinese Neurosurgical Congress is the highest level academic event for Chinese neurosurgeons around the world, which is held every two years and initiated by the World Chinese Neurosurgical Association. This congress discusses the development direction and theoretical frontiers of neurosurgery, focuses on the research level and research results of Chinese neurosurgery in the world, and provides a guiding impetus to the development of neurosurgery technology in China and even in the world. As the core agenda of this congress, the congress released the first clinical practice guideline for brain tumor diagnosis and treatment in China, i.e. the Chinese Molecular Diagnosis and Treatment Guidelines for Glioma, which was formulated by the Chinese Glioma Collaboration Group. The guideline was conducted under the guidance of Zhao Jizong, academician of Chinese Academy of Sciences, and Zhou Liangfu, academician of Chinese Academy of Engineering. The China Glioma Collaboration Group is led by Jiang Tao and Prof. Mao Ying, and its members are all the backbones of experts in the field of glioma research in China. Associate Professor Li Xuejun, an expert in neurosurgery from Xiangya Hospital of Central South University, participated in the drafting, modification and formulation of the guideline. Associate Professor Li Xuejun has long been engaged in the treatment and research of neurological tumors, and their team is at the forefront of glioma treatment in China, focusing on targeting molecular targets while pursuing precision surgery. Associate Professor Li Xuejun is the deputy director of Hunan Provincial Skull Base and Neurological Tumor Clinical Medical Technology Research Center, director of Molecular Pathology Room, and a recipient of the Hunan Provincial Education Department’s Young Backbone Teachers Cultivation Program. He was engaged in the research of targeted therapy for gliomas in the laboratories of Susan Knox and Martin Brown during his visit to Stanford Medical School in 2010-2012, and insisted on participating in the weekly Neurological Tumor Tumor Research Program at Stanford University. He insisted on participating in the weekly neurotumor tumor board at Stanford University, mastered the international advanced treatment concepts and research methods, and has applied for 4 national and provincial neurotumor topics after returning to China. “The emergence of the guideline brings an extremely high reference value for targeted therapy of gliomas.” According to Associate Professor Xuejun Li, the guideline eliminates as much as possible the arbitrariness and randomness that may arise in the process of targeted therapy for gliomas, with a view to achieving the core of molecularly targeted therapy-precision strikes. “Simply put, the guideline can be described as a ‘guiding light’ for targeted therapy of glioma,” he said. “Basic and clinical research on major brain diseases is the future direction of neurosurgery, as well as an important responsibility and obligation of our clinicians.” Associate Professor Li Xuejun said that although new means and methods are being introduced in the field of tumor treatment, there is a lack of corresponding efficacy assessment and professional review. “We believe that a new technology must be standardized before it is promoted. The development of this guideline provides great help for the rational treatment of gliomas and the establishment of clinical pathways.” Associate Professor Li Xuejun introduced that the core content of the guideline is: to establish a molecular detection and analysis system for gliomas based on evidence-based medicine, to describe the most prevalent glioma-associated molecular alterations, potential therapeutic targets, and biomarkers, which can then be used to guide clinical practice, to make therapeutic choices, and to determine the prognosis of patients. The ultimate goal: to reach the core of molecularly targeted therapy, i.e., hitting the target with precision. Chief：Wu Ximing http://www.xiangya.com.cn/web/Content.aspx?chn=284&id=24572